BC Innovations | Mar 26, 2019
Distillery Therapeutics

The short-chain fatty acid pentanoate for MS

DISEASE CATEGORY: Autoimmune disease INDICATION: Multiple sclerosis Cell culture and mouse studies suggest the short-chain fatty acid pentanoate could help treat MS. In primary mouse T helper type 17 (Th17) cells pentanoate increased expression of...
BC Week In Review | Feb 15, 2019
Company News

India's Glenmark spinning out innovative assets into U.S. unit

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) will spin out its innovation business to help accelerate its pipeline towards commercialization. The spinout will be a wholly owned subsidiary based in the U.S and have a new CEO...
BC Extra | Feb 14, 2019
Company News

India's Glenmark spinning out innovative assets into U.S. unit

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) will spin out its innovation business to help accelerate its pipeline towards commercialization. The spinout will be a wholly owned subsidiary based in the U.S and have a new CEO...
BC Innovations | Nov 13, 2018
Distillery Therapeutics

Hepatic

INDICATION: Liver fibrosis Patient sample and mouse studies suggest antagonizing AHR or RORγT could help treat liver fibrosis. In liver tissue samples from hepatitis patients, levels of IL-17A and IL-22, which are positively regulated by...
BC Innovations | Aug 29, 2018
Distillery Therapeutics

Inflammation

INDICATION: Inflammation Cell culture, mouse, rat and dog studies identified a RORγT inverse agonist that could help treat inflammation. Chemical synthesis and screening of a subset of Pfizer Inc.’s small compound library in a HEK-cell...
BC Innovations | Aug 23, 2018
Distillery Therapeutics

Inflammation

INDICATION: Inflammation In vitro and mouse studies identified a RORγT inverse agonist that could help treat delayed-type hypersensitivity (DTH)-associated inflammation. Fragment-based screening, chemical synthesis of phenyl-acetamide-based analogs of the screening hit, and in vitro and...
BC Extra | Apr 30, 2018
Company News

Allergan drops RORgammaT inhibitor for psoriasis

Allergan plc (NYSE:AGN) terminated development of VTP-43742 to treat psoriasis due to safety signals in a Phase II study, EVP and Chief R&D Officer C. David Nicholson said on the company's 1Q18 earnings call. The...
Clinical Results | Apr 20, 2018
Clinical Results

Lycera reports Phase I data for solid tumor candidate LYC-55716

Lycera Corp. (Ann Arbor, Mich.) reported data from 26 evaluable patients with relapsed or refractory solid tumors in the Phase I portion of the Phase I/IIa ARGON trial showing that oral LYC-55716 led to one...
BC Week In Review | Mar 16, 2018
Financial News

Escalier raises $19M series B

Escalier Biosciences B.V. (Nijmegen, Netherlands) raised $19 million on March 13 in a series B round led by Forbion. Existing investors New Science Ventures and BioGeneration Ventures also participated. Escalier plans to begin clinical trials...
BC Extra | Mar 13, 2018
Financial News

Escalier raises $19M series B

Escalier Biosciences B.V. (Nijmegen, Netherlands) raised $19 million in a series B round led by Forbion. Existing investors New Science Ventures and BioGeneration Ventures also participated. Escalier plans to begin clinical trials in mid-2018 of...
Items per page:
1 - 10 of 77